(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 0 | - |
Operating Income | -26.2MM | -24% |
Operating Expenses | 26.2MM | -24% |
Net Income | -23.7MM | -28% |
R&D | 15.3MM | -26% |
G&A | 10.9MM | -21% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (
Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Adverum Biotechnologies (ADVM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.
Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ADVM Announces Q4 and Full Year 2023 Results with Strategic Clinical and Corporate Developments
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million private placement financing with new and existing institutional investors - - Cash runway expected into late 2025 – - 1-for-10 reverse stock split to be effective March 21, 2024 - REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a